{"id":"NCT03160885","sponsor":"LEO Pharma","briefTitle":"Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)","officialTitle":"A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab Monotherapy in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-06-12","primaryCompletion":"2018-09-04","completion":"2019-08-14","firstPosted":"2017-05-19","resultsPosted":"2020-08-24","lastUpdate":"2025-03-11"},"enrollment":794,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis"],"interventions":[{"type":"DRUG","name":"Tralokinumab","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Initial treatment period - Tralokinumab Q2W","type":"EXPERIMENTAL"},{"label":"Initial treatment period - Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Maintenance treatment period - Tralokinumab Q2W","type":"EXPERIMENTAL"},{"label":"Maintenance treatment period - Tralokinumab Q4W","type":"EXPERIMENTAL"},{"label":"Maintenance treatment period - Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Maintenance treatment period - Placebo (tralokinumab naive)","type":"PLACEBO_COMPARATOR"},{"label":"Open-label treatment - Tralokinumab 300 mg Q2W + optional TCS","type":"EXPERIMENTAL"}],"summary":"Primary objective:\n\nTo evaluate the efficacy of tralokinumab compared with placebo in treating moderate to severe atopic dermatitis (AD).\n\nSecondary objectives:\n\nTo evaluate the efficacy of tralokinumab on severity and extent of AD, itch, and health related quality of life compared with placebo.\n\nMaintenance objective:\n\nTo evaluate maintenance of effect with continued tralokinumab dosing up to 52 weeks compared to placebo for subjects achieving clinical response at Week 16.","primaryOutcome":{"measure":"Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16.","timeFrame":"At Week 16","effectByArm":[{"arm":"Tralokinumab 300 mg Q2W","deltaMin":131,"sd":null},{"arm":"Placebo Q2W","deltaMin":22,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":115,"countries":["United States","Australia","Canada","Denmark","Italy","Poland","Russia","South Korea","United Kingdom"]},"refs":{"pmids":["40879371","40555305","40085349","37804473","37682422","36152216","33000465"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":592},"commonTop":["Dermatitis atopic","Upper respiratory tract infection","Viral upper respiratory tract infection","Conjunctivitis","Skin infection"]}}